{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:11:27Z","timestamp":1790626287258,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.pharma.2022.11.005","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T20:17:23Z","timestamp":1668197843000},"page":"419-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["D\u00e9tournement de la pr\u00e9gabaline \u00e0 des fins toxicomaniaques - \u00e9tat de la situation, risques et moyens de lutte"],"prefix":"10.1016","volume":"81","author":[{"given":"M.","family":"Laribi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chaouali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jaballah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Amira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hedhili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2022.11.005_bib0150","first-page":"227","article-title":"Calcium channel \u03b12\u2013\u03b4 ligands: gabapentin and pregabalin","volume":"8","author":"Thorpe","year":"2007","journal-title":"Comprehen Med Chem II"},{"key":"10.1016\/j.pharma.2022.11.005_bib0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review","volume":"81","author":"Kirk","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2022.11.005_bib0160","unstructured":"https:\/\/www.vidal.fr\/medicaments\/substan es\/pregabaline-22716.html."},{"key":"10.1016\/j.pharma.2022.11.005_bib0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel (2\u2013((alpha2\u2013delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pharma.2022.11.005_bib0170","unstructured":"Psycoacyif: Pregabaline (Lyrica), effets,_risques [En ligne] [consult\u00e9 le 20\u00a0d\u00e9cembre 2021] Disponible sur: https:\/\/www.psychoactif.org\/psychowiki\/index.php?title=Pregabaline_(Lyrica),_effets,_risques,_t%C3\u00a0%A9moignages."},{"key":"10.1016\/j.pharma.2022.11.005_bib0175","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40263-016-0390-z","article-title":"Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review","volume":"30","author":"Freynhagen","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharma.2022.11.005_bib0180","first-page":"575","article-title":"Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history","volume":"71","author":"Driot","year":"2016","journal-title":"Th\u00e9rapie"},{"key":"10.1016\/j.pharma.2022.11.005_bib0185","first-page":"1802291","article-title":"The association of gabapentin use and dose with substance use disorders prior to inpatient mental health treatment: a cross-sectional study","volume":"20","author":"Tomko","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.pharma.2022.11.005_bib0190","first-page":"9298571","article-title":"Nonmedical use of antihistaminergic anxiolytics and other prescription drugs among persons with opioid dependence","author":"Dahlman","year":"2016","journal-title":"J Addict"},{"key":"10.1016\/j.pharma.2022.11.005_bib0195","series-title":"Le r\u00e9seau fran\u00e7ais de pharmacovigilance: rapport d\u2019expertise sur la pr\u00e9gabaline [En, ligne]","year":"2020"},{"key":"10.1016\/j.pharma.2022.11.005_bib0200","series-title":"Observatoire fran\u00e7ais des drogues et des toxicomanies: nouvelle analyse annuelle du dispositif trend sur les drogues illicites ou d\u00e9tourn\u00e9es, leurs usagers et les, march\u00e9s","year":"2020"},{"key":"10.1016\/j.pharma.2022.11.005_bib0205","series-title":"Office des nations unies contre la drogue et le crime: rapport mondial sur les, drogues","year":"2019"},{"key":"10.1016\/j.pharma.2022.11.005_bib0210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2022.11.005_bib0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse Potential of Pregabalin","volume":"30","author":"Schjerning","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharma.2022.11.005_bib0220","first-page":"1","article-title":"The pattern of substance use disorder in the United Arab Emirates in 2015: results of a National Rehabilitation Centre cohort study","volume":"11","author":"Alblooshi","year":"2016","journal-title":"Subst Abuse Treatment Prevent Pol"},{"key":"10.1016\/j.pharma.2022.11.005_bib0225","series-title":"Minist\u00e8re de la sant\u00e9 de l\u2019\u00c9tat de Palestine et Institut national palestinien de sant\u00e9 publique, Estimating the extent of Illicit Drug Use in, Palestine","year":"2017"},{"key":"10.1016\/j.pharma.2022.11.005_bib0230","unstructured":"http:\/\/www.dpm.tn\/index.php\/medicament-a-usage-humain\/mms-par-classe th\u00e9rapeutique."},{"key":"10.1016\/j.pharma.2022.11.005_bib0235","series-title":"D\u00e9tournement de l\u2019usage de pr\u00e9gabaline par les toxicomanes. Communication au: Forum de la recherche de FPHM; 19-20\u00a0Nov 2021; Facult\u00e9 de Pharmacie de Monastir","author":"Sabrine","year":"2021"},{"key":"10.1016\/j.pharma.2022.11.005_bib0240","first-page":"37","article-title":"Toxicomanie \u00e0 la pr\u00e9gabaline par voie intranasale et troubles de la conduction cardiaque","volume":"29","author":"Dahan","year":"2017","journal-title":"Toxicol Anal Clin"},{"key":"10.1016\/j.pharma.2022.11.005_bib0245","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: an analysis of the european medicines agency's \u201csuspected adverse drug reactions\u201d database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharma.2022.11.005_bib0250","first-page":"S33","article-title":"Usage d\u00e9tourn\u00e9 de la pr\u00e9gabaline: \u00e0 propos de trois cas de d\u00e9c\u00e8s en r\u00e9gion marseillaise","volume":"32","author":"Caroline","year":"2020","journal-title":"Toxicol Anal Clin"},{"key":"10.1016\/j.pharma.2022.11.005_bib0255","doi-asserted-by":"crossref","first-page":"e1002965","DOI":"10.1371\/journal.pmed.1002965","article-title":"Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records","volume":"16","author":"Macleod","year":"2019","journal-title":"PLOS Med"},{"key":"10.1016\/j.pharma.2022.11.005_bib0260","series-title":"Medicine Use and Spending in the U.S","author":"Institute IQVIA.","year":"2019"},{"key":"10.1016\/j.pharma.2022.11.005_bib0265","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/1556-4029.14021","article-title":"Gabapentin-related deaths: patterns of abuse and postmortem levels","volume":"64","author":"Tharp","year":"2019","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.pharma.2022.11.005_bib0270","article-title":"Pregabalin and gabapentin to be reclassifed as Class C controlled substances","author":"Burns","year":"2019","journal-title":"Pharmaceutical J"},{"key":"10.1016\/j.pharma.2022.11.005_bib0275","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/02791072.2020.1734695","article-title":"Preliminary evidence of pregabalin misuseamong prescription and\/or illicit opioid misusers","volume":"52","author":"Buttram","year":"2020","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.pharma.2022.11.005_bib0280","first-page":"12","article-title":"Pharmacist awareness and attitudes regarding gabapentinoid abuse","volume":"17","author":"Evoy","year":"2018","journal-title":"TSHP J"},{"key":"10.1016\/j.pharma.2022.11.005_bib0285","unstructured":"https:\/\/www.ordre.pharmacien.fr\/Communications\/Les-actualites\/Pregabaline-Lyrica-et-generiques-modification-des-conditions-de-prescription-et-delivrance-pour-limiter-le-mesusage."},{"key":"10.1016\/j.pharma.2022.11.005_bib0145","unstructured":"https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000039659116."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:37:41Z","timestamp":1757720261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922001481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003450922001481"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.005","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9tournement de la pr\u00e9gabaline \u00e0 des fins toxicomaniaques - \u00e9tat de la situation, risques et moyens de lutte","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}